【摘要】 目的：对新型钾离子竞争性酸阻滞剂富马酸伏诺拉生片进行药品评价，为医疗机构遴选该药品提供参考。方法：使用《中国医疗机构药品评价与遴选快速指南》(以下简称《快速指南》)的评价维度、评价细则及评价方法，对富马酸伏诺拉生片进行药品评价。结果：基于《快速指南》,富马酸伏诺拉生片的总评分为73.8分；其中，药学特性18.8分，有效性18分，安全性9分，经济性14分，其他指标14分。结论：富马酸伏诺拉生片的推荐意见为强推荐。《快速指南》能帮助医疗机构快速地评价与遴选药品，有在医疗机构推广的潜力和价值。更多还原

【Abstract】 OBJECTIVE: To perform drug evaluation on the new potassium-competitive acid blocker Vonoprazan fumarate tablets, so as to provide reference for medical institutions to select the drug. METHODS: Evaluation dimensions, rules and methods of Rapid Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(hereinafter referred to as “Rapid Guideline”) were used to evaluate the Vonoprazan fumarate tablets. RESULTS: Based on Rapid Guideline, the total score of Vonoprazan fumarate tablets was 73.8. Among them, 18.8 points for pharmacological properties, 18 points for effectiveness, 9 points for safety, 14 points for economy and 14 points for other indicators. CONCLUSIONS: The recommendation for Vonoprazan fumarate tablets is strong. Rapid Guideline can help medical institutions to evaluate and select drugs quickly, and has the potential and value to be promoted in medical institutions.更多还原